$crvs
Corvus Pharmaceuticals' soquelitinib shows promising clinical data and novel ITK inhibition, but faces valuation concerns and scrutiny from short sellers.
About $crvs
Corvus Pharmaceuticals is a biotechnology company focused on developing novel therapeutics.
Engagements: [------] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [------]
[--] Month: [---------] +272%
[--] Months: [---------] +117%
[--] Year: [---------] +57%
1-Year High: [-------] on 2026-01-20
1-Year Low: [-----] on 2025-03-16
Engagements by network (24h): X: [------] YouTube: [--] Reddit: [--]
Mentions: [---] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
1-Year High: [---] on 2026-01-29
1-Year Low: [--] on 2025-03-16
Mentions by network (24h): X: [---] YouTube: [--] Reddit: [--]
Creators: [---] (24h)
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning $crvs in the last [--] hours which is down 26% from [---] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2026-01-21
1-Year Low: [--] on 2025-03-16
The most influential creators that mention $crvs in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @financebully | [--] | [-----] | [--] | [-----] |
| @tradingsssss | [--] | [-----] | [--] | [-----] |
| @A_May_MD | [--] | [------] | [--] | [-----] |
| @semodough | [--] | [------] | [--] | [-----] |
| @HOThomasWPhelps | [--] | [-----] | [--] | [-----] |
| @seedy19tron | [--] | [------] | [--] | [-----] |
| @BiotechTV | [--] | [------] | [--] | [-----] |
| @ShortSeller | [--] | [------] | [--] | [---] |
| @paxtrader777 | [--] | [---] | [--] | [---] |
| @zethedeuce | [--] | [---] | [--] | [---] |
Sentiment: 73%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 73%
Daily Average: 92%
[--] Month: 73% +13%
[--] Months: 73% -27%
[--] Year: 73% -22%
1-Year High: 100% on 2025-02-18
1-Year Low: 49% on 2025-10-26
Most Supportive Themes:
- Positive Clinical Data and Analyst Upgrades: (40%) Multiple posts highlight positive clinical trial data for soquelitinib, particularly in atopic dermatitis, and recent analyst upgrades, such as Mizuho raising the price target to $30.
- Novel Mechanism of Action (ITK Inhibition): (30%) There's significant discussion around Corvus's novel ITK inhibitor mechanism, which aims to reset the immune system by modulating T-cell phenotypes, differentiating it from existing therapies.
- Potential for Broader Applications and Long-Term Benefit: (20%) Posts suggest the ITK inhibition mechanism could have broader applications beyond atopic dermatitis and may lead to long-lasting immune memory or disease remission, potentially reducing the need for continuous treatment.
Most Critical Themes:
- Valuation Concerns and Short Seller Reports: (70%) Some posts raise concerns about the company's high valuation relative to its current stage (early Phase 2) and reference short seller reports questioning the data and commercial viability.
- Comparison to Competitors and Market Pricing: (30%) Discussions compare Corvus's drug to competitors like Dupilumab and JAK inhibitors, with some arguing that the market is pricing in certainty for a blockbuster drug that may not materialize.
Top $crvs Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"$NKTR $CRVS $NKTR $CRVS don't understand the animosity between the two names both work on tregs and $NKTR's data provides a nice read through to $CRVS drug and vice versa most BPs talk about this and this is being talked about the same way with $ABVX and obefazimod in IBD but a safe $NKTR $CRVS don't understand the animosity between the two names both work on tregs and $NKTR's data provides a nice read through to $CRVS drug and vice versa most BPs talk about this and this is being talked about the same way with $ABVX and obefazimod in IBD but a safe"
X Link @tradingsssss 2026-02-15T00:33Z [----] followers, [----] engagements
"@lfholt nice. $evmn and $nmra now in top [--] ytd. $anl $eras $ibrx $alms $crvs $nika $elvn $catx"
X Link @financebully 2026-02-14T23:35Z [----] followers, [---] engagements
"@mrhighway_y @dbruhzinski3 i'm a fan and investor of $crvs $acrs and $arqt. i also think $apge $kymr $evmn and trex bio have commercial promise in atd. i don't think nktr has commercial promise. the end"
X Link @financebully 2026-02-14T22:56Z [----] followers, [---] engagements
"@semodough 100%. $nktr $crvs will be the leaders in AtD"
X Link @wz2013 2026-02-14T22:34Z [---] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing